Anzeige
❌
Mehr »
Donnerstag, 22.10.2026 - Börsentäglich über 12.000 News
Gewinnsprung und Milliardenmarkt im Rücken - 40 Mio. USD Auftragsbestand durch Methan-Altlasten
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
XM

WKN: A2JDJS | ISIN: US98420P3082 | Ticker-Symbol: XMS
Tradegate
19.10.26 | 15:03
0,258 Euro
-3,01 % -0,008
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
XTANT MEDICAL HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
XTANT MEDICAL HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2520,27007:59
0,2560,26807:30

Aktuelle News zur XTANT MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.09.Lucid Capital initiates Xtant Medical stock with buy rating1
XTANT MEDICAL Aktie jetzt für 0€ handeln
11.08.Xtant Medical auf der Canaccord Genuity Konferenz: Wachstumsplan setzt auf Biologika2
11.08.Xtant outlines $99M-$103M 2026 revenue guidance while integrating Dilon sales force2
11.08.Xtant Medical misses top-line and bottom-line estimates; lowers FY2026 outlook1
11.08.Xtant Medical Holdings, Inc. - 10-Q, Quarterly Report2
11.08.Xtant Medical Holdings, Inc.: Xtant Medical Reports Second Quarter 2026 Financial Results331Launched Trivium Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to...
► Artikel lesen
07.08.Xtant Medical Holdings, Inc. - 8-K, Current Report2
13.05.Xtant Medical raises FY 2026 revenue guidance to $101M-$105M as it adds HEMOBLAST distribution rights1
13.05.Xtant Medical stock rating maintained at Buy by BTIG on guidance raise1
13.05.BTIG bestätigt Kaufempfehlung für Xtant Medical nach Prognoseanhebung1
13.05.Xtant Medical Holdings Q1 2026 Earnings Call Transcript1
13.05.Xtant Medical GAAP EPS of -$0.02, revenue of $20.9M, raises FY guidance1
13.05.Xtant Medical Holdings, Inc. - 10-Q, Quarterly Report2
13.05.Xtant Medical Holdings, Inc. - 8-K, Current Report-
13.05.Xtant Medical Holdings, Inc.: Xtant Medical Reports First Quarter 2026 Financial Results923Raises full-year 2026 revenue guidance to a range of $101-$105 million Significantly strengthens balance sheet Enters into exclusive U.S. distribution agreement...
► Artikel lesen
31.03.Xtant Medical Holdings, Inc.: Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results265Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total...
► Artikel lesen
11.12.25Xtant Medical Holdings, Inc.: Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata Synthetic Bone Graft284nanOss Strata is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation...
► Artikel lesen
01.12.25Companion Spine LLC Completes Acquisition of the Business and Assets of Paradigm Spine GmbH, including the Coflex and CoFix Spine Implants and All Other Implant Systems, from Xtant Medical Holdings, Inc.621Companion Spine is the first company in the world with a product portfolio solely focused on Total Disease State Solutions ("TDS") for degenerative spine diseases. This acquisition creates...
► Artikel lesen
01.12.25Xtant Medical Holdings, Inc.: Xtant Medical Completes Sale of its Coflex Assets and Paradigm OUS Businesses to Companion Spine252BELGRADE, Mont., Dec. 1, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions...
► Artikel lesen
10.11.25Xtant Medical Holdings, Inc.: Xtant Medical Reports Third Quarter 2025 Financial Results319Total Revenue of $33.3 Million Increased 19% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Reiterates FY25 Revenue Guidance...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1